C-peptide is a cleavage product of proinsulin that acts on different type of cells, such as blood and endothelial cells. C-peptide biological effects may be different in type 1 and type 2 diabetes. Besides, there are further evidence for a functional interaction between C-peptide and insulin. In this way, C-peptide has ambiguous effects, acting as an antithrombotic or thrombotic molecule, depending on the physiological environment and disease conditions. Moreover, C-peptide regulates interaction of leucocytes, erythrocytes, and platelets with the endothelium. The beneficial effects include stimulation of nitric oxide production with its subsequent release by platelets and endothelium, the interaction with erythrocytes leading to the generation of adenosine triphosphate, and inhibition of atherogenic cytokine release. The undesirable action of C-peptide includes the chemotaxis of monocytes, lymphocytes, and smooth muscle cells. Also, C-peptide was related with increased lipid deposits and elevated smooth muscle cells proliferation in the vessel wall, contributing to atherosclerosis.
peptide on kidney, 10 retina, 11 and nerve. [12] [13] [14] High doses of C-peptide were capable to reduce thrombus formation. 15 It increases microvascular blood flow in the skin of T1DM patients, possibly by stimulating Na + , K + -ATPase activity and nitric oxide (NO) production. 16 NO production stimulated by C-peptide has beneficial effects on reduction of erythrocytes and leukocyte-endothelium interaction in vitro, which has been found beneficial for cardiovascular complications. 17, 18 Some studies demonstrated that C-peptide has been able to improve erythrocyte deformability in T1DM patients by increasing Na + , K + -ATPase activities. 19, 20 Importantly, these beneficial effects were mostly observed in T1DM when compared to T2DM patients.
On the other hand, studies have demonstrated that the deposit C-peptide on intima layer of the vessels promotes infiltration of monocytes/macrophages and lymphocyte CD4 + , with impacts on the atherogenesis process. 21, 22 Besides, it induces proliferation and migration of vascular smooth muscle cells (VSMC), promoting both the atherosclerosis development during diabetes along with neointima formation. 23 However, under hyperglycemic condition, administration of C-peptide to rat aortic smooth muscle cells (RASMCs)
reduced the proliferation and migration of VSMC. 24 Although these evidences suggest several actions of C-peptide, the mechanism associated to these effects is poorly understood. In this context, the present review aimed at exploring the potential role of C-peptide on blood cells and its effects on atherosclerosis process.
Importantly, C-peptide replacement therapy alone or in combination with insulin may be useful in the prevention and treatment of vascular complications in diabetes.
| METHODS
This narrative review is based on previously published studies on the topic in the English language, through a search performed in PubMed, Cochrane, Scopus, and Web of Science databases, using the term C-peptide AND platelets or erythrocytes or nitric oxide or leukocyte or endothelium or atherosclerosis, with no date or type of studies restrictions.
Articles were selected if they focused on C-peptide action in the title or abstract. After eliminating duplicate literatures, we selected potentially eligible reports. Studies that focused on measurement of C-peptide as a diagnostic and monitoring tool were excluded. We included in this review 100 studies published between 1988 and 2018, in English language. The reference list of selected articles was also hand-searched for additional relevant studies ( Figure 1 ).
3 | RESULTS 3.1 | Mechanism of C-peptide action based on ATP production by erythrocytes C-peptide may exert physiological effects on several cell types resulting in different biological activities. 1 A single study performed with T1DM patients and healthy subjects showed that C-peptide did not present direct effect on platelet activation. 25 However, an in vitro study involving immobilized endothelial cells suggested that C-peptide was able to inhibit platelet adhesion to endothelium in the presence of erythrocytes. 26 An important role has been attributed to erythrocytes due to generation and scavenging of NO, which determine NO availability in the vasculature. 27 Besides the regulation of vascular tone, NO is responsible for inhibiting of platelet activation and aggregation. 28, 29 It has been reported that, in the absence of erythrocytes, alterations in shear stress alone did not stimulate the generation of NO in the pulmonary circulation in the rabbit lung. 30 Medawala et al proposed that C-peptide is able to stimulate adenosine triphosphate (ATP) production by erythrocytes, which induces NO production in both endothelium and platelets. 31 Nonetheless, stimulation leading to the production of ATP by erythrocytes only occurs in the presence of Zn
2+
. 32 Liu et al revealed that albumin delivers Zn 2+ and C-peptide to erythrocytes. Upon delivery, there was an increase in erythrocyte-derived ATP of approximately 45%, as well as an increase in endothelium-derived NO. 33 Thus, the ATP released from erythrocytes seems to be related to the induction of NO production in endothelial cells.
On microcirculation, ATP binds to specific purinergic receptors and promotes NO liberation by endothelial cells. 34 NO released acts directly on erythrocyte membrane, and consequently improves erythrocyte deformability. 20 Healthy human erythrocytes treated with C-peptide in the presence of Zn 2+ were capable to enhance NO production in bovine pulmonary artery endothelial cells, in comparison to untreated cells. Nevertheless, when bovine pulmonary artery FIGURE 1 Description of systematic search in literature endothelial cells were incubated with an inhibitor to P2Y receptor, which impairs the ATP binding, and erythrocytes treated with C-peptide/Zn 2+ were pumped beneath them, difference in the NO production could not be observed, suggesting the ATP participation on the induction of NO production through an erythrocyte-mediated mechanism. 32 In this context, a possible mechanism for the C-peptide action on platelets and endothelium is based on ATP production by erythrocytes (Figure 2 ).
Correlating the presence of metals with C-peptide effect on . Importantly, this release is due to an increase in glucose transport via GLUT1 transporter. 35 However, in a subsequent study with T2DM rats, Meyer et al showed that Zn
-activated C-peptide displayed a reduced ATP release from erythrocytes, as compared with controls. This effect was corrected by metformin. 36 It was demonstrated that plasminogen activator inhibitor, type 1 (PAI-1), a human endothelial and platelet protein, is presented in higher levels in diabetic patients than in healthy individuals, which may contribute to an increased risk of thrombosis in diabetes mellitus. 37 19 Similarly, the same samples incubated with C-peptide or its fragments C-terminal pentapeptide or hexapeptide presented improvement on erythrocyte deformability, in a wide range of shear stress, reaching similar levels of the healthy controls. 46 Furthermore, pretreatment with ouabain completely abolished C-peptide-mediated restoration of erythrocyte deformability indicating that C-peptide's effect is dependent on Na + , K + -ATPase.
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In T1DM, the Na + , K + -ATPase activity is reduced in a variety of tissues and cells. 47, 48 To emphasize the importance of Na ) shear rates. The resultant findings indicated that C-peptide treatment was not able to alter the blood viscosity of any sample.
Moreover, at high shear rate, diabetic patients presented increased blood and plasma viscosity, while at low shear rate, T2DM patients presented lower blood viscosity and erythrocyte aggregation, despite the raised proaggregatory peptides. The authors hypothesized that this is probably due to the less deformable erythrocytes. (HbA1c) levels. 52 Identical results were obtained using erythrocytes from T2DM patients, and the ATP levels were restored to similar levels of healthy controls. 35 In order to evaluate the mechanism involved on C-peptide- In addition, hyperglycemia is the main factor associated with vascular complications in diabetes, 58 which is accompanied by reactive oxygen species (ROS) production. 59 ,60 Yet, the mechanisms underlying the beneficial activity of C-peptide on the vasculature in hyperglycemia remains poorly understood. However, recently, the potential mechanism of C-peptide action in experimentally induced diabetic nephropathy in rats was investigated by Elbassuoni et al. C-peptide injection resulted in a significant decrease in fasting blood glucose and in an increase in blood insulin level in treated group when compared to diabetic group. Moreover, the results indicated that NO in part mediates the beneficial effects of C-peptide, since its beneficial effects were partially antagonized with L-NAME combination. Importantly, C-peptide treatment was also associated with decrease in serum levels of urea, creatinine, TNF-α and angiotensin II, and renal tissue level of malondialdehyde. On the other hand, it was observed increased renal levels of total antioxidant capacity, NO and B cell CLL/lymphoma 2 (BCL-2). The authors concluded that C-peptide deficiency might contribute to metabolic and renal errors, since treatment with C-peptide corrected those changes. 61 In a diabetic mice model, C-peptide promoted endothelial cell proliferation, migration, and tube formation, which are critical for angiogenesis in wound healing. Besides, C-peptide accelerated angiogenesis via stimulation of extracellular signal-regulated kinase (ERK ½), Akt and NO production, using human umbilical vein endothelial cells (HUVEC). 62 However, in another study with diabetic mice, C-peptide had no effect on wound healing. Importantly, it was observed an increase in the number of leukocytes adherent to endothelium in C-peptide-treated diabetic mice compared with control animals.
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C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NADPH oxidase ROS generation in human aortic endothelial cells. 64 The C-peptide protective effects, e.g., prevention
of hyperglycemia-induced endothelial apoptosis and ROS generation, occur through AMP-activated protein kinase α (AMPKα) activation, which inhibits ROS generation by NADPH oxidase and mitochondria. 65 Moreover, C-peptide also prevents hyperglycemia-induced endothelial apoptosis via inhibition of intracellular ROS-mediated activation of transglutaminase 2 (TG2), a pathway that mediates endothelial cell death. 66 Reduced apoptotic cell rate mediated by C-peptide can be explained also through its capability to reduce caspase-3 activity, a cell death protease, and to enhance BCL-2, an antiapoptotic factor. 64 The mechanism underlying C-peptide antioxidant effect could be also due to the restoration of mitochondrial complex I activity, which is impaired on hyperglycemia, and inhibition of vascular endothelial growth factor (VEGF), another agent involved on ROS production. C-peptide's action over the complex I activity improves mitochondrial respiration, which leads to ATP generation and reduced ROS. 67 Similarly, VEGF-induced stress fibre formation inhibition by C-peptide promotes endothelium integrity, diminishing intracellular ROS generation in endothelial cells. 8 Besides ROS production, another feature of a dysfunctional endothelium is impaired NO generation. NO deficiency leads to vascular damage, resulting in inappropriate blood flow and exposure of blood vessels to atherogenesis and thrombosis. 68 C-peptide reverses the depletion of NO and its deficiency consequences in many tissues. 16, 19, 69, 70 This effect is potentiated when combined with insulin at a concentration of 1 μU/mL, being more expressive at higher C-peptide concentrations. 71 On T2DM, residual secretion of C-peptide is related to preservation of endothelial function and decrease in oxidative stress. 72 Treatment with C-peptide has been associated to increase of eNOS transcription on lung and aortic segments from rats and human cavernosal SMC. 73, 74 These data suggest that elevation of eNOS transcription may be one possible explanation for the increase of basal NO during C-peptide treatment.
In addition, C-peptide has also been reported to inhibit leukocyteendothelium interaction. Accordingly, C-peptide was able to attenuate leukocyte rolling, adherence, and transmigration after administration of NG-nitro-L-arginine methyl ester, L-NAME (a NO biosynthesis inhibitor), or thrombin (to promote inflammatory stimuli) in rat mesentery tissue. The inhibition of leukocyte-endothelium interaction after C-peptide administration was associated with decreased surface expression of the cell adhesion molecules P-selectin and intercellular adhesion molecule 1 (ICAM-1) on the microvascular endothelium.
Therefore, C-peptide led to an upregulation of endothelial nitric oxide synthase (eNOS)-also known as nitric oxide synthase 3 (NOS3)-transcription and activity, augmenting NO release from aorta. 73 A previous report also showed that endogenous NO may regulate leukocyte activation within the pulmonary circulation of rabbits. 75 Altogether, these results suggest that NO also mediates inhibition of leukocyteendothelium interaction through the action of the C-peptide.
It is known that leukocytes express eNOS. 76, 77 In addition, NO inhibition with L-NAME, in mesenteric venules of Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR), promoted acute inflammation with increased rates of leukocyte adhesion and emigration in venules. 78 NO inhibited leucocyte adhesion to the vessel wall by interfiring with the ability of CD11b/CD18 to bind to the endothelial cell surface. 79 However, the role for leukocyte eNOS in NO signalling by C-peptide remains controversial.
Contrary, Wallerath et al did not observe any changes in eNOS
phosphorylation, after C-peptide treatment of bovine aortic endothelial cells. The stimulation of these cells with C-peptide enhanced intracellular calcium. Since eNOS is regulated by calcium/calmodulin, the calcium influx is imperative to eNOS activity. 70 Moreover, on a molecular view, C-peptide-induced eNOS transcription could be explained through the increase on ERK ½ and p38 mitogen-activated protein kinase (p38MAPK) activities, as observed on LEII mouse lung capillary endothelial cells. 80 In kidney, differently from other tissues, C-peptide suppresses eNOS gene expression. In fact, Kamikawa et al, using T1DM rats, observed a significant enhancement of eNOS protein in glomerulus and renal afferent arterioles of these animals. C-peptide infusion abrogated eNOS expression on diabetic kidney by suppressing PKCα, an isoform, usually activated on kidney during diabetes. 81 Finally, a summary of the beneficial effects of C-peptide on blood and endothelial and smooth muscle cells is shown in Figure 3 .
| C-peptide and atherosclerosis
The high glucose levels in circulation directly contribute to endothelial injury by irreversible glycation of subendothelial collagen and other structural proteins of the vessels, resulting in AGEs. 82 The interactions Since migration and proliferation of SMC are associated with diabetic macroangiopathy, assessing the mechanism by which C-peptide acts on SMC is important. 86 In a human CD4+ chemotaxis assay, treatment of lymphocytes T CD4+ with pertussis toxin inhibited the C-peptide-induced migration on these cells, demonstrating the role of the pertussis toxin-sensitive G-proteins on this process. Interestingly, some G protein-coupled receptor activate PI3-K, and pertussis toxin is also a PI3-K inhibitor. Likewise, treatment with other PI3-K inhibitors (wortmannin or LY294002) also blocked the cell migration.
However, when the cells are treated with C-peptide alone, it was observed an increase in PI3-Kγ (an isoform of PI3-k) activity. Intriguingly, pretreatment of CD4+ with pertussis toxin inhibits C-peptideinduced PI3-Kγ activation, suggesting that the pertussis toxin-sensitive G-proteins acts on the upstream of this metabolic pathway. 22 Notably, just as it occurs with monocytes/macrophages and VSMC, the C-peptide promotes the infiltration and deposition of lymphocytes CD4+ on the early atherosclerotic lesions.
Regarding the fatty streak development process, infiltration of proinflammatory cells, mainly CD4+ lymphocytes, besides foam cells and VSMC on the vessel wall is a crucial step. VSMCs proliferate in
FIGURE 3
Modulation of haemostatic and inflammatory responses by C-peptide. C-peptide may inhibit cytokine secretion by leukocytes and, consequently, endothelial monolayer expression of adhesion molecules, such as ICAM-1, VCAM-1, and P-selectin, that bind cognate ligands on leukocytes. Moreover, these leukocytes secrete inflammatory mediators and growth factors that can promote the migration and proliferation of smooth muscle cells, which also may be directly prevented by C-peptide. In addition, erythrocytes are thought to contribute to the regulation of systemic NO bioavailability by releasing ATP when subjected to hypoxia or shear stress. This induce eNOS expression in endothelium and NO production by platelets. Endothelium eNOS-derived NO production might be involved in the regulation of erythrocyte deformability, through Na + K + ATPase activity. High ATP levels are also related to platelet inhibition of PAI-1 expression and impairment of platelet activation and aggregation. In relation to apoptosis, C-peptide may reduce TG2 and caspase-3 activation and enhance BCL-2 activity. Ultimately, C-peptide reduces ROS generation through AMPKα activation and VEGF inhibition. Thus, C-peptide might present beneficial effects in the homeostasis and inflammation process, which triggers the thrombus formation that causes most acute complications of atherosclerosis. Abbreviations: AMPKα, AMP-activated protein kinase alfa; ATP, adenosine triphosphate; BCL-2, B cell CLL/lymphoma 2; eNOS, endothelial nitric oxide synthase; ICAM-1, intercellular adhesion molecule 1; NO, nitric oxide; PAI-1, plasminogen activator inhibitor, type 1; PLT, platelets; ROS, reactive oxygen species; TG2, transglutaminase 2; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor However, C-peptide does not stimulate CD4+ lymphocyte chemotaxis by ERK1/2, p38 and Akt. 88 Counterpoising these findings, some authors demonstrated the C-peptide beneficial effects against atherogenesis (Table 1) However, patients with early T2DM and insulin resistance have elevated serum levels of C-peptide, and an increased cardiovascular risk has been reported in these patients. 94 In addition, several studies in individuals without diabetes showed positive correlation between Cpeptide levels and the incidence of several cardiovascular diseases, such as coronary artery disease and myocardial infarction. [95] [96] [97] Altogether, these data suggest that elevated C-peptide levels, due to insulin resistance, contribute to atherosclerosis vascular disease in these patients. On the other hand, C-peptide replacement in T1DM patients exerts a beneficial influence on development of microvascular complications, since this disease is marked by serum peptide deficiency. 13, 98 In addition, C-peptide infusion increases the hyperemic myocardial blood flow and left-ventricular function inT1DM patients. 99 These data suggest that C-peptide replacement therapy might play a role in preventing and potentially reverse some of the chronic diabetes complication, especially due to its ability to improve blood flow, in this group. 100 However, the atheroprotective role of C-peptide in T1DM patients remains unclear, and further studies in animal models and humans are thus warranted. In the same way, the proatherogenic role of C-peptide in T2DM patients has not been well investigated.
| Final comments and conclusions
There is significant evidence of beneficial action of C-peptide, involving the release of ATP by erythrocytes, which stimulates NO production by platelets and endothelial cells. NO improves blood flow, inhibits erythrocyte adherence to endothelium, and mediates inhibition of leukocyte-endothelium interaction. In respect to the endothelium, treatment using C-peptide diminishes ROS generation and, therefore, reduces vascular damage. Besides, it enhances NO production by endothelial cells, contributing to increase vasodilation and blood flow. By other side, C-peptide may reduce cytokine release leading to a decreased expression of adhesion molecules on the endothelium.
As for C-peptide involvement in atherosclerosis, the data are controversial. Noteworthy, the studies indicating a positive relation between C-peptide and atherosclerosis occurrence, unlike those which defend the beneficial effects against the disease, were in general based on evaluation of C-peptide only on the vessel wall, without the interference of hyperglycemia or insulin treatment in diabetic subjects. Moreover, C-peptide seems to act biologically different according to the environment in T1DM, in T2DM, or in nondiabetic individuals. Importantly, the effects of C-peptide alone and in combination with insulin are not the same and depend on the concentration and ratio of these peptides. These facts could explain the different findings seen on the literature. 
